cagrilintide vs eloralintide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: Amylin receptor · full Obesity pipeline
cagrilintide
Developed by Novo Nordisk
NCT03856047 · Phase 2 · completed
The trial randomized participants to five active doses, a pooled placebo, and an active liraglutide comparator arm, with quadruple-blinding (participant, care provider, investigator, and outcomes assessor all masked) and roughly 100 participants per arm. The primary endpoint, percent change in body weight at 26 weeks, is the regulator-accepted physiological measure for obesity trials, and every cagrilintide dose showed a statistically significant weight-loss advantage over placebo (p-values ranging from 0.0002 to <.0001), so the primary comparison was clearly met in the favorable direction.
Next expected readout: January 2027 · NCT07411560 (registry estimate)
Reported efficacy
Change in Body Weight (%) (From baseline (week 0) to week 26): Change in Body Weight (%) (From baseline (week 0) to week 26): Cagrilintide 0.3 mg -6.1% (Standard Deviation 3.9) | Cagrilintide 0.6 mg -6.9% (Standard Deviation 5.4) | Cagrilintide 1.2 mg -8.5% (Standard Deviation 5.4) | Cagrilintide 2.4 mg -9.5% (Standard Deviation 6.2) | Cagrilintide 4.5 mg -10.8% (Standard Deviation 5.5) vs Liraglutide 3.0 mg -8.5% (Standard Deviation 5.6) | Pooled Placebo -3% (Standard Deviation 5.2) (met)
Result source: NCT03856047
eloralintide
Developed by Eli Lilly
NCT06230523 · Phase 2 · completed
Randomized, double-blind, placebo-controlled phase 2 in obesity and overweight (263 participants). Week-48 body-weight reductions ranged from 9.4% to 20.1% across eloralintide doses versus 0.4% on placebo, a separation many times larger than the reported error margins; percent change in body weight is the accepted registrational endpoint in obesity.
Next expected readout: December 2026 · NCT07738614 (registry estimate)
Reported efficacy
Percent Change From Baseline in Body Weight at Week 48 (Baseline, Week 48): Body weight, percent change from baseline at Week 48: eloralintide 1 mg -9.4%, 3 mg -12.4%, 6 mg -17.6%, 9 mg -20.1%, 6/9 mg -19.9% and 3/6/9 mg -16.5% vs placebo -0.4%. (met)
Result source: NCT06230523
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | cagrilintide | eloralintide |
|---|---|---|
| Body weight, % change | -10.8% vs -3%−7.8 vs placeboNCT038560474 other results
| -20.1% vs -0.4%−19.7 vs placeboNCT062305235 other results
|
| Weight loss of 5% or more | 88.7% vs 30.9%+57.8 vs placeboNCT038560474 other results
| 92.7% vs 31.2%+61.5 vs placeboNCT062305235 other results
|
| Weight loss of 10% or more | 53.5% vs 10.4%+43.1 vs placeboNCT038560474 other results
| 82.3% vs 12.8%+69.5 vs placeboNCT062305235 other results
|
| Waist circumference, change (cm) | -9.5 vs -3.4−6.1 vs placeboNCT038560474 other results
| —Trial running · NCT07321886 |
Body weight, % change
- cagrilintide
- -10.8% vs -3%−7.8 vs placeboNCT03856047
4 other results
- -9.5% vs -3% NCT03856047
- -8.5% vs -3% NCT03856047
- -6.9% vs -3% NCT03856047
- -6.1% vs -3% NCT03856047
- eloralintide
- -20.1% vs -0.4%−19.7 vs placeboNCT06230523
5 other results
- -19.9% vs -0.4% NCT06230523
- -17.6% vs -0.4% NCT06230523
- -12.4% vs -0.4% NCT06230523
- -9.4% vs -0.4% NCT06230523
- -16.5% vs -0.4% NCT06230523
Weight loss of 5% or more
- cagrilintide
- 88.7% vs 30.9%+57.8 vs placeboNCT03856047
4 other results
- 74.1% vs 30.9% NCT03856047
- 75.8% vs 30.9% NCT03856047
- 62.0% vs 30.9% NCT03856047
- 57.5% vs 30.9% NCT03856047
- eloralintide
- 92.7% vs 31.2%+61.5 vs placeboNCT06230523
5 other results
- 97.5% vs 31.2% NCT06230523
- 85.0% vs 31.2% NCT06230523
- 87.1% vs 31.2% NCT06230523
- 71.5% vs 31.2% NCT06230523
- 90.8% vs 31.2% NCT06230523
Weight loss of 10% or more
- cagrilintide
- 53.5% vs 10.4%+43.1 vs placeboNCT03856047
4 other results
- 44.0% vs 10.4% NCT03856047
- 35.8% vs 10.4% NCT03856047
- 24.1% vs 10.4% NCT03856047
- 15.3% vs 10.4% NCT03856047
- eloralintide
- 82.3% vs 12.8%+69.5 vs placeboNCT06230523
5 other results
- 91.1% vs 12.8% NCT06230523
- 76.6% vs 12.8% NCT06230523
- 60.5% vs 12.8% NCT06230523
- 53.3% vs 12.8% NCT06230523
- 79.2% vs 12.8% NCT06230523
Waist circumference, change (cm)
- cagrilintide
- -9.5 vs -3.4−6.1 vs placeboNCT03856047
4 other results
- -8.1 vs -3.4 NCT03856047
- -7.7 vs -3.4 NCT03856047
- -6.2 vs -3.4 NCT03856047
- -6.2 vs -3.4 NCT03856047
- eloralintide
- —Trial running · NCT07321886
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. cagrilintide: 4 of 5 rows · eloralintide: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | cagrilintide | eloralintide |
|---|---|---|
| Weight absolute change · kg | -11.8 vs -3.2 placebo kg @ 26wk4.5 mga,b,c,d NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 show 4 more doses-10.1 vs -3.2 placebo kg @ 26wk2.4 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 -9 vs -3.2 placebo kg @ 26wk1.2 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 -7.1 vs -3.2 placebo kg @ 26wk0.6 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 -6.6 vs -3.2 placebo kg @ 26wk0.3 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 | -21 vs -0.2 placebo kg @ 48wk6/9 mga,b,c,d NCT06230523 · Phase 2 show 5 more doses-21.3 vs -0.2 placebo kg @ 48wk9 mg NCT06230523 · Phase 2 -18.7 vs -0.2 placebo kg @ 48wk6 mg NCT06230523 · Phase 2 -13.3 vs -0.2 placebo kg @ 48wk3 mg NCT06230523 · Phase 2 -10.2 vs -0.2 placebo kg @ 48wk1 mg NCT06230523 · Phase 2 -18 vs -0.2 placebo kg @ 48wk3/6/9 mg NCT06230523 · Phase 2 |
| Dropout rate | 6.9%4.5 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 show 4 more results1%2.4 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 3.9%1.2 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 3%0.6 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 4%0.3 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 | 20.8%6/9 mge NCT06230523 · Phase 2 show 5 more results11.1%9 mg NCT06230523 · Phase 2 25%6 mg NCT06230523 · Phase 2 20.8%3 mg NCT06230523 · Phase 2 46.4%1 mg NCT06230523 · Phase 2 11.5%3/6/9 mg NCT06230523 · Phase 2 |
| Discontinued due to AEs | —4.5 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 show 4 more results—2.4 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 —1.2 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 —0.6 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 —0.3 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 | 0%6/9 mge NCT06230523 · Phase 2 show 5 more results1.9%9 mg NCT06230523 · Phase 2 3.6%6 mg NCT06230523 · Phase 2 0%3 mg NCT06230523 · Phase 2 7.1%1 mg NCT06230523 · Phase 2 3.8%3/6/9 mg NCT06230523 · Phase 2 |
| Serious AEs | 4%4.5 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 show 4 more results2.9%2.4 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 6.9%1.2 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 2%0.6 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 5.9%0.3 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 | 8.3%6/9 mge NCT06230523 · Phase 2 show 5 more results5.6%9 mg NCT06230523 · Phase 2 3.6%6 mg NCT06230523 · Phase 2 4.2%3 mg NCT06230523 · Phase 2 10.7%1 mg NCT06230523 · Phase 2 1.9%3/6/9 mg NCT06230523 · Phase 2 |
| Most frequent reported AEs | 4.5 mg nausea 46.5% (placebo 17.8%) constipation 20.8% (placebo 6.9%) fatigue 19.8% (placebo 3%) NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 show 4 more results2.4 mg nausea 31.4% (placebo 17.8%) diarrhoea 17.6% (placebo 8.9%) constipation 16.7% (placebo 6.9%) NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 1.2 mg nausea 36.3% (placebo 17.8%) nasopharyngitis 12.7% (placebo 9.9%) headache 10.8% (placebo 11.9%) NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 0.6 mg nausea 27% (placebo 17.8%) diarrhoea 10% (placebo 8.9%) constipation 9% (placebo 6.9%) NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 0.3 mg nausea 19.8% (placebo 17.8%) diarrhoea 14.9% (placebo 8.9%) constipation 10.9% (placebo 6.9%) NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 | 6/9 mge nausea 54.2% (placebo 13.2%) fatigue 45.8% (placebo 11.3%) upper respiratory tract infection 20.8% (placebo 11.3%) NCT06230523 · Phase 2 show 5 more results9 mg fatigue 42.6% (placebo 11.3%) nausea 33.3% (placebo 13.2%) constipation 24.1% (placebo 5.7%) NCT06230523 · Phase 2 6 mg nausea 64.3% (placebo 13.2%) diarrhoea 35.7% (placebo 9.4%) fatigue 28.6% (placebo 11.3%) NCT06230523 · Phase 2 3 mg constipation 16.7% (placebo 5.7%) arthralgia 12.5% (placebo 5.7%) fatigue 12.5% (placebo 11.3%) NCT06230523 · Phase 2 1 mg benign prostatic hyperplasia 14.3% (placebo 15.4%) constipation 14.3% (placebo 5.7%) covid-19 14.3% (placebo 3.8%) NCT06230523 · Phase 2 3/6/9 mg nausea 25% (placebo 13.2%) fatigue 21.2% (placebo 11.3%) diarrhoea 17.3% (placebo 9.4%) NCT06230523 · Phase 2 |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 26 weeks versus 48 weeks.
- ePopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
cagrilintide
show 4 more results
show 4 more results
eloralintide
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: cagrilintide's landscape · eloralintide's landscape